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Leukaemia comprises four main groups of conditions: acute
myeloid leukaemia (AML), acute lymphoblastic leukaemia (ALL),
chronic lymphocytic leukaemia (CLL) and chronic myeloid
leukaemia (CML). Acute lymphoblastic leukaemia is mainly seen
in children and AML is most commonly seen in adults and half of
all are aged more than 60 years. Chronic lymphocytic leukaemia is
a condition of the elderly and CML is seen in most age groups from
older children onwards.
CLINICAL PRESENTATION
The presenting features of leukaemia depend very much on the
type. Acute leukaemias tend to have quite a sudden onset, usually
over a few weeks, with symptoms of bone marrow failure resulting
in infection, bruising and tiredness or dyspnoea on account of
anaemia. Some patients, particularly children, may have bone pain
as a presenting feature. There are no characteristic symptoms that
separate the clinical features of AML and ALL. Chronic
lymphocytic leukaemia is now diagnosed in 80% of patients as a
chance finding of lymphocytosis in a patient having a blood test
for some other condition. Symptomatic patients may present with
lymphadenopathy or splenomegaly, and may have symptoms of
anaemia or recurrent infections because of low immunoglobulin
levels. Chronic myeloid leukaemia is associated with a very high
white cell count and significant splenomegaly. The condition can
develop insidiously and usually results in symptoms of tiredness
owing to anaemia, weight loss or night sweats, and abdominal
bloating or discomfort because of splenomegaly.
DIAGNOSIS
The first step in the diagnosis is usually for the primary care
physician to arrange a blood count. Morphological examination
of this by an expert is often enough to give reasonable certainty of
the diagnosis; however, in the majority of instances, a bone
marrow aspirate and biopsy will be required to confirm
the diagnosis. Exceptions to this may be in the elderly where
active treatment is not offered and the peripheral white cell count
is unequivocal. Immunophenotyping of leukaemia cells is key
to confirming the diagnosis in acute leukaemias and CLL.
Increasingly, cytogenetic analysis, by conventional banding,
FISH and PCR for informative translocations and deletions, allows
subclassification of leukaemia and prognostic stratification.
This is now used to inform clinical trial design where
patients falling into poor prognostic categories may be offered
different treatments. There are two areas where cytogenetic
evaluation is critical. These are acute promyelocytic leukaemia
associated with the PML-RARA fusion gene, t(15;17), and
CML characterised by the Philadelphia chromosome (t(9;22)).
It is probable that in the future, additional information about
diagnosis and prognosis will be provided by gene profiling
and proteomics, but these are not presently part of routine
diagnostic practice.
TREATMENT
Acute myeloid leukaemia
Acute myeloid leukaemia is principally a disease of the elderly.
For fitter patients, induction therapy is usually a combination of
anthracycline with cytarabine. Depending on age, between 60 and
80% of patients will achieve complete remission. Consolidation
treatment of a further two to four additional cycles is usually given.
For younger patients, an overall survival (OS) of between 40
and 50% can be attained, but the results are not as good for those
aged more than 60 years. The reasons for this are the greater
frequency of adverse cytogenetic abnormality and increased
P-glycoprotein activity together with increasing comorbidities. It
is likely that further increase in dose intensity will not be possible
because of toxicity and newer strategies are needed. These may
include targeted therapy using FLT3 inhibitors and HIDAC
inhibition. Early results of targeted immunotherapy with
gemtuzumab ozogamycin are also encouraging. Trials of stem cell
autografting have not demonstrated superiority. Allografting has a
powerful antileukaemic effect, but this is counterbalanced by high
toxicity resulting in a relatively small OS gain. Conventional
myeloablative allografting is applicable to only a very small
proportion of the overall AML population because of age and
donor availability. Reduced intensity allografts may be safer and
more easily deliverable to an older population but their efficacy
has yet to be established. In older patients with comorbidity
treatment outcomes have not improved. Low-dose cytarabine
increases OS compared with supportive care, but the results
remain very poor. New ideas are needed for this group, as it is
apparent that conventional chemotherapy adds little except to a
small cohort with good-risk cytogenetics. *Correspondence: Dr DW Milligan; E-mail: d.w.milligan@bham.ac.uk
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Overall, 80% of patients with CLL will be diagnosed with a chance
blood test. Of these only about one-quarter will require treatment
and the majority will die of a cause other than CLL. When
treatment is needed, UK practice has been to use chlorambucil;
however, a recent trial indicated that better and more durable
disease responses can be achieved using fludarabine and cyclopho-
sphamide, in combination. NICE currently does not support the
use of fludarabine monotherapy as first-line treatment in CLL.
Newer treatments include antibody treatment with rituximab and
alemtuzumab and it remains to be seen how the advent of these
agents will influence the natural history of the disease. Currently,
CLL remains incurable without a stem cell allograft and allograft-
ing is not widely applicable to this population.
Chronic myeloid leukaemia
The standard of care for the duration of this study was a-interferon.
Patients unable to tolerate this were treated with hydroxycarbamide.
Patients treated with interferon had a median duration of survival of
approximately 5 years. Younger patients with a donor were offered a
stem cell transplant resulting in an OS for this cohort of between 40
and 70%, depending on age. The advent of the tyrosine kinase (TK)
inhibitor, imatinib, has now changed the landscape in CML. The
majority of patients will now achieve a cytogenetic complete
response with some patients having disease undetectable by
sensitive PCR tests. For patients treated since 2000, median survival
has not yet been reached and 90% of patients can now expect to live
5 years. The newer TK inhibitors may overcome TK mutations and
may further improve the outlook.
COMMENTARY
The principal difficulty that I have as a clinician with the
epidemiological data presented by Rachet et al in this issue,
pp S116–S118 is the grouping of all types of leukaemia together.
Even within AML there is considerable heterogeneity and we can
subclassify patients according to cytogenetic and other risk factors.
Sequential trial data from the UK MRC trials (now NCRI) has
demonstrated a continuous improvement in outcomes, particu-
larly in younger patients. This is in part because of better
supportive care and the ability to deliver more toxic regimens.
Some cytogenetic subgroups are doing particularly well and the
introduction of differentiation treatment with all-trans retinoic
acid or arsenic trioxide in acute promyelocytic leukaemia has
made a very substantial impact in this cohort. In CML the TK
inhibitors are almost certainly making a substantial impact on
survival but this is not yet being seen in population based studies,
partly because the data is too immature and partly because as a
population of all patients with leukaemia the numbers are small.
However, these real gains are lost in the noise generated by the lack
of precision of the data. For this information to become really
meaningful we will need much better classification of leukaemia at
registration.
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